Neurogene Inc.
NGNE Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$23.55
KIRA · Stoqly’s AI analyst, in plain words
- Neurogene Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Neurogene Inc. lost $90.4M in fiscal 2025.
- Free cash flow was −$78.4M in fiscal 2025, — of revenue.
Market cap
$531M
P/E
—
Revenue
$0.0M
Net income
−$90.4M
Free cash flow
−$78.4M
Operating margin
—
Neurogene Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$90.4M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Neurogene Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 24, 2026
- Legal name
- Neurogene Inc.
- CIK
- 0001404644
Neurogene Inc. · NGNE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $1.6M | $0.0M | $0.9M | $0.0M |
| Revenue growth | — | 8,226.3% | −100.0% | — | −100.0% |
| Net interest income | $0.0M | $1.6M | — | — | — |
| Operating margin | −319,463.2% | −3,572.5% | — | −8,930.3% | — |
| Net income | −$60.7M | −$55.2M | −$36.3M | −$75.1M | −$90.4M |
| Net margin | −319,431.6% | −3,488.6% | — | −8,123.7% | — |
| Diluted EPS | −$1.10 | −$1.04 | — | −$4.28 | −$4.24 |
| Cash | |||||
| Cash from operations | −$47.6M | −$52.8M | −$51.4M | −$70.6M | −$77.2M |
| Capital expenditure | $3.3M | $2.2M | $0.3M | $0.8M | $1.2M |
| Free cash flow | −$50.8M | −$55.1M | −$51.7M | −$71.4M | −$78.4M |
| FCF margin | −267,478.9% | −3,480.0% | — | −7,720.1% | — |
| Share count change | 6.2% | 0.3% | — | — | 21.4% |
| Debt and strength | |||||
| Cash and short-term investments | $142M | $82.0M | $197M | $312M | $269M |
| Shareholders' equity | −$91.9M | −$146M | $186M | $310M | $265M |
| Current ratio | 16.7x | 12.7x | 8.7x | 20.8x | 16.6x |
| Interest coverage | — | −28,258.5x | −4,631.9x | −6,883.8x | −20,665.6x |
| Returns and quality | |||||
| Return on equity | −122.2% | — | −180.3% | −30.3% | −31.4% |
| Return on tangible equity | — | — | −19.5% | −24.2% | −34.1% |
| Piotroski F-score | — | 2 | — | — | 1 |
| Altman Z'' | −9.6 | −17.7 | 6.2 | 14.5 | 11.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.1M
4 insiders
Of sales under plans
100%
$1.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Neurogene Inc. · NGNE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $23.55 a share, the company is worth $531M.
Source: SEC EDGAR XBRL filings (CIK 0001404644). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.